A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.


We conducted the analysis within four days, which included a review of a comprehensive data room encompassing preclinical, clinical, regulatory, manufacturing and IP matters. Our report identified the areas of key risk in the project and suggested how to mitigate them.


Related Case Studies